Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Position Lowered by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,251 shares of the medical research company’s stock after selling 142 shares during the period. Geneos Wealth Management Inc.’s holdings in Thermo Fisher Scientific were worth $2,212,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Fifth Third Bancorp lifted its stake in Thermo Fisher Scientific by 11.6% during the fourth quarter. Fifth Third Bancorp now owns 335,053 shares of the medical research company’s stock valued at $174,305,000 after purchasing an additional 34,917 shares during the last quarter. apricus wealth LLC boosted its stake in shares of Thermo Fisher Scientific by 37.3% during the 4th quarter. apricus wealth LLC now owns 600 shares of the medical research company’s stock worth $312,000 after acquiring an additional 163 shares in the last quarter. Goelzer Investment Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 5.4% in the 4th quarter. Goelzer Investment Management Inc. now owns 819 shares of the medical research company’s stock worth $426,000 after acquiring an additional 42 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of Thermo Fisher Scientific by 11.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 2,387 shares of the medical research company’s stock valued at $1,242,000 after purchasing an additional 250 shares during the last quarter. Finally, CX Institutional increased its stake in Thermo Fisher Scientific by 26.1% in the 4th quarter. CX Institutional now owns 9,960 shares of the medical research company’s stock worth $5,182,000 after purchasing an additional 2,062 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Up 0.1 %

Shares of TMO stock opened at $575.21 on Monday. The company has a market capitalization of $220.02 billion, a price-to-earnings ratio of 36.06, a PEG ratio of 3.82 and a beta of 0.76. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The stock’s 50 day simple moving average is $533.60 and its 200 day simple moving average is $569.58. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Thermo Fisher Scientific announced that its board has initiated a share buyback plan on Friday, November 15th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

Several research analysts have commented on the stock. Barclays decreased their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Evercore ISI reduced their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Scotiabank assumed coverage on Thermo Fisher Scientific in a report on Monday, December 23rd. They set a “sector perform” rating and a $605.00 price target on the stock. Finally, TD Cowen raised their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Four analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $648.95.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the sale, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at approximately $58,960,669.92. This trade represents a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 34,850 shares of company stock worth $19,123,197 in the last quarter. 0.34% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.